Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
Authors
Keywords
-
Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 44, Issue 3, Pages 197-207
Publisher
Oxford University Press (OUP)
Online
2014-01-29
DOI
10.1093/jjco/hyt201
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Late Release of Circulating Endothelial Cells and Endothelial Progenitor Cells after Chemotherapy Predicts Response and Survival in Cancer Patients
- (2015) Jeanine M. Roodhart et al. NEOPLASIA
- A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
- (2013) Stephen R. D. Johnston et al. BREAST CANCER RESEARCH AND TREATMENT
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
- (2013) L. S. Schwartzberg et al. CLINICAL CANCER RESEARCH
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
- (2013) B. P. Schneider et al. CLINICAL CANCER RESEARCH
- Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
- (2013) David M. Hyams et al. INVESTIGATIONAL NEW DRUGS
- Diagnostic Value of Contrast-Enhanced Ultrasound Parametric Imaging in Breast Tumors
- (2013) Zhang Yuan et al. Journal of Breast Cancer
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- 18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer
- (2013) J. Cheng et al. JOURNAL OF NUCLEAR MEDICINE
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Role of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in the Management of Hepatocellular Carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan
- (2013) Masatoshi Kudo et al. ONCOLOGY
- Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
- (2013) R. Joseph Bender et al. PLoS One
- A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
- (2013) José Baselga et al. Trials
- A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
- (2012) Massimo Cristofanilli et al. BREAST CANCER RESEARCH AND TREATMENT
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- Baseline Tumor Oxygen Saturation Correlates with a Pathologic Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
- (2012) S. Ueda et al. CANCER RESEARCH
- Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
- (2012) John R. Mackey et al. CANCER TREATMENT REVIEWS
- A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
- (2012) William J. Gradishar et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in locally advanced or metastatic breast cancer
- (2012) William J Gradishar EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies
- (2012) Nathalie Lassau et al. INVESTIGATIVE RADIOLOGY
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
- (2012) Robert S. Kerbel JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Evaluation of Breast Tumor Blood Flow with Dynamic First-Pass 18F-FDG PET/CT: Comparison with Angiogenesis Markers and Prognostic Factors
- (2012) A. Cochet et al. JOURNAL OF NUCLEAR MEDICINE
- Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
- (2012) Jean-Yves Pierga et al. LANCET ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
- (2012) James P. B. O'Connor et al. Nature Reviews Clinical Oncology
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
- (2012) Christoph Thomssen et al. ONCOLOGY
- Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging—Prospective Assessment
- (2012) Ukihide Tateishi et al. RADIOLOGY
- Potential Application Value of Contrast-Enhanced Ultrasound In Neoadjuvant Chemotherapy of Breast Cancer
- (2012) Xiaoli Cao et al. ULTRASOUND IN MEDICINE AND BIOLOGY
- Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
- (2012) José R. Rossari et al. Journal of Oncology
- First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
- (2011) Kenjiro Aogi et al. BREAST CANCER RESEARCH AND TREATMENT
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
- (2011) Nicholas J. Robert et al. Clinical Breast Cancer
- A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial
- (2011) G. Mariani et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
- (2011) Xavier Pivot et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunomodulatory effects of anti-angiogenic drugs
- (2011) A Heine et al. LEUKEMIA
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
- (2010) I. E. Smith et al. ANNALS OF ONCOLOGY
- Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
- (2010) H. Wildiers et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Antiangiogenic Therapies in Early-Stage Breast Cancer
- (2010) Christina Derleth et al. Clinical Breast Cancer
- Antiangiogenic strategies in breast cancer management
- (2010) Monica Giovannini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
- (2010) Katalin Boér et al. INVESTIGATIONAL NEW DRUGS
- TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer
- (2009) John Mackey et al. Clinical Breast Cancer
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
- (2009) J. Baar et al. CLINICAL CANCER RESEARCH
- An overview of small-molecule inhibitors of VEGFR signaling
- (2009) S. Percy Ivy et al. Nature Reviews Clinical Oncology
- VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
- (2008) H. J. Burstein et al. CLINICAL CANCER RESEARCH
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
- (2008) C. Desmedt et al. CLINICAL CANCER RESEARCH
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More